SEC Form 4 · accession 0001231919-26-001197
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Scott M Rocklage
10% Owner
John D Diekman
10% Owner
5AM Ventures II LP
10% Owner
5AM CO-INVESTORS II LP
10% Owner
5AM Partners II, LLC
10% Owner
Kush Parmar
10% Owner
5AM Ventures VII, L.P.
10% Owner
5AM Partners VII, LLC
10% Owner
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 6:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001516551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 16, 2026 | S | 32,607 | $1.91 | D | 142,463 | I | By 5AM Ventures II, L.P. |
| Common StockF1,F3 | Sep 16, 2026 | S | 1,285 | $1.91 | D | 5,616 | I | By 5AM Co-Investors II, L.P. |
| Common StockF4 | holding | — | — | — | 981,269 | I | By 5AM Ventures VII, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- F3The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- F4The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Remarks
On August 24, 2026, the Issuer effected a 1-for-8 reverse stock split of its Common Stock, which is reflected in the Reporting Persons' number of securities beneficially owned reported in this filing.